Fig. 2From: Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimodAssessment of disease activity and treatment response in PANGAEA 2.0. In the first study phase disease activity will be assessed according to Lublin et al. [7]. Disease active patients who switch to fingolimod are subjected to a 3-year observation period. Disease progression and treatment response will be assessed by using the modified Rio score [8] (figure adapted from [10]). Definition of active disease by Lublin et al. 2014 and evaluation of disease progression and treatment response by the modified Rio ScoreBack to article page